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Objective: Acellularized porcine heart valve scaffolds have been successfully used
for heart valve tissue engineering, creating living functioning heart valve tissue.
However, there is concern about the possibility of porcine endogenous retrovirus
transmission. In this study we investigated whether acellularized porcine heart valve
scaffold causes cross-species transmission of porcine endogenous retrovirus in a
sheep model.
Methods: Acellularized porcine pulmonary valve conduits (n  3) and in vitro
autologous repopulated porcine pulmonary valve conduits (n  5) were implanted
into sheep in the pulmonary valve position. Surgery was carried out with cardio-
pulmonary bypass support. The animals were killed 6 months after the operation.
Blood samples were collected regularly up to 6 months after the operation and tested
for porcine endogenous retrovirus by means of polymerase chain reaction and
reverse transcriptase-polymerase chain reaction. In addition, explanted tissue-engi-
neered heart valves were tested for porcine endogenous retrovirus after 6 month in
vivo.
Results: Porcine endogenous retrovirus DNA was detectable in acellularized porcine
heart valve tissue. However, 6 months after implantation of in vitro and in vivo
repopulated acellularized porcine heart valve scaffolds, no porcine endogenous
retrovirus sequences were detectable in heart valve tissue and peripheral blood.
Conclusion: Acellularized porcine matrix scaffolds used for creation of tissue-
engineered heart valves do not transmit porcine endogenous retrovirus.
Heart valve tissue engineering using scaffold matrix from alloge-neic and xenogeneic biological sources resulted in functioning,living heart valves.1-3 Due to the shortage of allogeneic 3-dimen-sional heart valve scaffolds, acellularized xenogeneic scaffoldsare an attractive alternative for heart valve tissue engineering.However, there is concern about the possibility of porcine endog-
enous retrovirus (PERV) transmission.4 This concern is supported by the findings
from various groups who demonstrated PERV infection of human cell lines and
primary human endothelial cells in vitro.5-7
The acellularization process for biological matrix scaffolds might not remove all
native cells or cell debris.8 Moreover, we recently showed that after acellularization
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of porcine tissue, up to 2% of native DNA is still detectable
within the matrix.9 These findings might indicate an in-
crease risk for cross-species PERV transmission after im-
plantation of acellularized porcine tissue. However, there
are no data available indicating whether these cell remnants
or DNA fragments are capable of PERV transmission.
To elucidate this problem, tissue-engineered heart valves
based on acellularized porcine heart valve scaffolds were
implanted into sheep for 6 months, after which the valvular
tissue was assessed for PERV by means of polymerase
chain reaction (PCR) and reverse transcription PCR (RT-
PCR). Furthermore, blood samples were drawn regularly for
up to 6 months to detect PERV DNA/RNA.
Methods
Acellularization of Valve Conduits
Porcine pulmonary valve conduits (n 8) were obtained from pigs
(German landrace) ranging from 25 to 30 kg from the Tierzuchan-
stalt Mariensee. Hearts were obtained under sterile conditions, and
pulmonary valve conduits were harvested with a thin ridge of
subvalvular muscle tissue proximally and a short segment of the
truncus pulmonalis distally. The valve conduits were stored at 4°C.
Within 30 minutes, the valve conduits were placed in a bioreactor
for acellularization. The conduits were placed in a bioreactor filled
with 0.05% trypsin (Biochrom) and 0.02% ethylenediaminetet-
raacetic acid (EDTA; Biochrom) for 48 hours, followed by flush-
ing with phosphate-buffered saline solution for 48 hours to remove
all cell debris. All steps were conducted in an atmosphere of 5%
CO2 and 95% air at 37°C with the bioreactor rotating at a speed of
7 rpm, respectively, 21 rpm. Samples of the conduit were taken
before and after treatment to document complete acellularization
of the conduit.
Cell Isolation and Culture
The technique of cell isolation and cell culture have been described
in detail elsewhere.1,10 For the generation of autologous cell cul-
ture, short segments of the right carotid artery were harvested from
5 lambs.
Cell Seeding
The acellularized porcine valve conduits (n  5) were seeded first
with myofibroblasts and coated with endothelial cells, resulting in
a uniform cellular restitution of the pulmonary valve conduit
surface. Three separate cycles of myofibroblast and endothelial
cell seeding were performed. In each cycle 1 106 myofibroblasts
or endothelial cells were seeded onto the xenogeneic pulmonary
valve scaffold fixed into a bioreactor and cultured in static nutrient
medium (Dulbecco’s modified Eagle’s medium, GIBCO,
Karlsruhe, Germany) for 4 hours (37°C, 5% CO2), followed by
rotating of the bioreactor (12 hours, 0.1 rpm). Samples of the
conduit were taken to document seeding of myofibroblast and
endothelial cells.
Pulmonary Valve Conduit Replacement
Eighteen days after the initial cell seeding, the repopulated pul-
monary valve conduits were implanted into the same 5 lambs from
which the initial vessels harvested (age 10 to 12 weeks, weight 25
to 30 kg), and the acellularized porcine heart valve scaffolds were
implanted in the remaining 3 sheep. The technique has been
described in detail elsewhere1; in brief, the heart was exposed by
a left anterolateral thoracotomy, by means of femoral arterial and
right atrial venous cannulation, and normothermic cardiopulmo-
nary bypass was established. With the heart beating, the pulmo-
nary artery was transected, all 3 native leaflets removed, and the
valve conduits implanted. All animals received humane care in
compliance with the “Guidelines for the Care and Use of Labora-
tory Animals” published by the National Institutes of Health
(National Institutes of Health publication No. 85-23, revised
1985).
Histology and Immunohistochemistry
The acellularization treatment was documented by hematoxylin-
eosin staining. Histological characterization was performed by
means of standard hematoxylin-eosin and Movat-Pentachrom
staining. Immunohistochemical staining for endothelial cell char-
acterization was performed by use of the avidin-biotin-peroxidase
technique (factor VIII-related antigen; primary antibody, von Wil-
lebrandt factor; clone 8/86, DAKO). For characterization of myo-
cytes and fibroblasts, a double immunofluorescence technique with
monoclonal antibodies against myocytes (monoclonal desmin an-
tibody; clone C-18, Santa Cruz Biotechnology, Santa Cruz, Calif)
and fibroblasts (polyclonal vimentin antibody; clone Vim H-84,
Santa Cruz Biotechnology) were used.
DNA and RNA Isolation from Tissue
Porcine acellularized and explanted in vitro and in vivo repopu-
lated heart valves were homogenized in a solution containing 4
mol/L guanidine thiocyanate, 25 mmol/L sodium citrate, 0.5%
Sarkosyl, and 0.1 mol/L 2-mercaptoethanol. Homogenate (1 mL)
was mixed with 0.1 mL 2 mol/L sodium acetate (pH 4). Water-
saturated phenol (1 mL) was added after several inversions and
thoroughly mixed, and 0.2 mL of 49:1 chloroform/isoamyl alcohol
was added. Incubation occurred for 15 minutes at 4°C. After
centrifugation for 20 minutes at 10,000 g, 4°C, the aqueous RNA-
containing phase was transferred in a second tube. The interphase
and lower organic phase were used for precipitate DNA.
DNA Precipitation
Pure (100%) ethanol (0.3 mL) was added per 1 mL of solution and
incubated for 5 minutes at room temperature and centrifuged at
2000 g for 5 minutes at 4°C. Protein containing supernatant was
removed. The DNA pellet was washed twice in 0.1 mol/L sodium
citrate and resuspended in 75% ethanol, then incubated for 20
minutes at room temperature. The dried DNA pellet was dissolved
in 8 mmol/L NaOH and centrifuged at 12,000 g for 10 minutes.
The supernatant was transferred to a new tube, DNA was quanti-
fied by reading the A260, and 0.5 to 1 g was added to the PCR
mix.
RNA Precipitation
RNA was precipitated by adding 1 mL of 100% isopropanol to the
aqueous phase, incubated for 30 minutes at 20°C, then centri-
fuged 10,000 g for 10 minutes at 4°C. RNA pellet was dissolved
and precipitated by adding 0.3 mL 100% isopropanol. Incubation
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was for 30 minutes at 20°C. The pellet was washed with 75%
ethanol. The supernatant was discarded and the pellet dried. RNA
was dissolved in 100 to 200 L diethylpyrocarbonate-treated
water, incubated for 15 minutes at 55°C, and stored at 70°C.
RNA was quantified by reading the A260 and A280; 1 g was used
for RT-PCR.
In Vitro Isolation of Peripheral Blood Monocytes from
Whole Blood
Ficoll-Paque gradient was prepared according to the manufactur-
er’s instructions. Anticoagulant-treated blood was layered on the
Ficoll-Paque solution and centrifuged at 400 g for 40 minutes at
20°C. Differential migration during centrifugation results in the
formation of layers containing different blood cell types. First, the
upper layer of plasma was discarded. Then the lymphocyte layer
was transferred to a clean centrifuge tube. Two washing steps
followed, adding 3 volumes of balanced salt solution; centrifuga-
tion at 100 g for 10 minutes at 20°C followed that. The supernatant
was removed, and the lymphocytes in pellets were homogenized in
denaturing solution.
Isolation of DNA and Total RNA of Peripheral Blood
Monocytes and Tissue
The cusps of 1 heart valve and Ficoll-Paque–isolated peripheral
blood monocytes (PBMCs) were homogenized in a denaturing
solution containing 4 mol/L guanidine thiocyanate, 25 mmol/L
sodium citrate, 0.5% N-lauroyl-sarcosine (Sarkosyl), and 0.1
mol/L 2-mercaptoethanol. One milliliter of homogenate was mixed
with 0.1 mL of 2 mol/L sodium acetate (pH 4). After several
inversions, 1 mL of water-saturated phenol was added and thor-
oughly mixed, and 0.2 mL of 49:1 chloroform/isoamyl alcohol was
added. The suspension was incubated for 15 minutes at 4°C. After
centrifugation at 10,000 g for 20 minutes at 4°C, the aqueous
RNA-containing phase was transferred into a second tube. The
interphase and lower organic phase were used to precipitate DNA.
Purification of Viral RNA from Plasma
For purification of viral RNA from human plasma, Qiagen
QiAamp viral RNA Mini Kit (Qiagen GmbH, Hilden, Germany)
was used. Viral RNA preparation was done according to the
manufacturer’s instructions.
PERV-Specific PCR and RT-PCR
These methods were performed according to the PERV pol-spe-
cific PCR/RT-PCR of Patience and colleagues5 and porcine-spe-
cific RT-PCR of Heneine and associates.11 For cDNA synthesis, 1
g of total RNA and avian myeloblastosis virus–reverse transcrip-
tase (Boehringer Mannheim, Germany) was used. PCR was done
with 1 g of DNA. PCR products were separated on 2% agarose
gel in an ethidium bromide–tris-acetate-EDTA buffer.
Results
All animals survived the operation and had an uneventful
postoperative course.
Histological and Immunohistological Evaluation
The acellularization procedure resulted in a complete cell.
Tissue-engineered valves showed a complete seeding of
myofibroblasts and endothelial cells of the valve (seeding
controls not transplanted) and conduit wall, evaluated by
positive staining for von Willebrandt factor and vimentin
desmin double immunofluorescence technique. Further-
more, the interstitium of the tissue-engineered pulmonary
valve conduit showed a fibroblast and myocyte population
similar to native ovine valve tissue. The Movat penta-
chrome stain showed amounts of stainable collagen, glycos-
aminoglycans, proteoglycans, and elastin similar to native
ovine valve tissue.
PERV Sequences in Heart Valve Tissue
Two cusps of 1 heart valve and half of the surrounding
annulus from 3 different porcine heart valves were used to
isolate RNA and DNA. In acellularized porcine scaffolds
PERV DNA was detectable. However, 6 months after im-
plantation no PERV-specific sequences (PERV-specific
PCR and RT-PCR) could be amplified in in vivo and in vitro
repopulated heart valves (Figure 1).
PERV Sequences in Sheep after Implantation
Examination of peripheral blood monocytes and plasma of
sheep by means of PERV-specific PCR (PERV-specific
PCR and RT-PCR) revealed negative results up to 6 months
after implantation of tissue-engineered heart valves based
on acellularized porcine scaffolds (Figure 2).
Discussion
The search for an ideal heart valve substitute meeting the
criteria outlined by Harken and Curtis12 led to the develop-
ment of tissue-engineered heart valves; tissue engineering
involves the reconstitution of viable autologous tissue on
3-dimensional scaffolds.13,14 Biodegradable polymer scaf-
folds as well as acellularized scaffold matrix from biologi-
cal sources have been successfully used, creating function-
ing, living heart valve tissue.1-3,15-17 However, biological
scaffolds have the advantages of preserved extracellular
matrix proteins important for cellular attachment.18,19 We
recently showed that both biological scaffold sources (allo-
geneic and xenogeneic) used for heart valve tissue engineer-
ing will result in living heart valve tissue.1,2 The lack of
acellularized autologous scaffold material favors acellular-
ized xenogeneic scaffolds as a scaffold material for heart
valve tissue engineering. However, little is known about the
safety of acellularized porcine tissue in terms of cross-
species infection with PERV.
The safety of porcine tissue for xenotransplantation has
been questioned recently by Patience and colleagues5 and
Wilson and coworkers,6 who demonstrated that PERV is
capable of infecting human cell lines in vitro. However,
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cross-species transmission of PERV to patients exposed to
living pig tissue for a limited time could not be demonstrat-
ed.13,20 Moza and coworkers21 showed that glutaraldehyde-
treated porcine heart valves do not carry PERV DNA, and
patients receiving porcine heart valves do not show any
signs of PERV infection up to 3 years after implantation of
glutaraldehyde treated porcine heart valves. Whether chem-
ical acellularization of porcine tissue used for tissue engi-
Figure 1. PERV sequences in in vivo and in vitro repopulated heart valves 6 months after implantation. Lane 1,
marker; lane 2, positive control (PCR of DNA from native porcine heart valve with porcine-specific primer); lane
3, PCR of DNA from acellularized porcine heart valve with porcine-specific primer; lane 4, negative control (PCR
of DNA from native ovine heart valve with porcine-specific primer); lane 5, marker; lanes 6 to 8, PCR of DNA from
sheep 6 months after implantation of acellularized porcine pulmonary valve scaffolds with PERV-specific primers;
lanes 9 to 13, PCR of DNA from sheep 6 months after implantation of acellularized porcine pulmonary valve
scaffolds repopulated in vitro with autologous ovine cells with PERV-specific primers, lane 14, marker.
Figure 2. Plasma probes of sheep and PCR of DNA from PBMCs after implantation of tissue-engineered heart
valves based on porcine acellularized heart valve scaffolds. Lane 1, marker; lane 2, positive control (PCR of porcine
plasma with PERV-specific primers); lane 3, negative control (ovine plasma cells with PERV-specific primer); lane
4, marker; lanes 5 to 7, PCR of DNA from sheep plasma 6 months after implantation of acellularized porcine
pulmonary valve scaffolds with PERV-specific primers; lanes 8 to 12, PCR of DNA from sheep plasma 6 months after
implantation of acellularized porcine pulmonary valve scaffolds repopulated in vitro with autologous ovine cells
with PERV-specific primers; lane 13, marker; lane 14, negative control (ovine PBMCs with PERV-specific primers);
lane 15, positive control (porcine PBMCs with PERV-specific primers); lane 16, marker; lanes 17 to 19, PBMCs of
sheep 6 months after implantation of acellularized porcine pulmonary valve scaffolds with PERV-specific primers);
lanes 20 to 24, PBMCs of sheep 6 months after implantation of acellularized porcine pulmonary valve scaffolds
repopulated in vitro with autologous ovine cells with PERV-specific primers; lane 25, marker.
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neering prevents PERV infection has not been delineated so
far. In this context, however, Zeltinger and coworkers8
observed residual cell remnants after chemical acellulariza-
tion of porcine heart valves. Furthermore, we demonstrated
that after chemical acellularization of porcine tissue, up to
2% of native DNA is still detectable within the matrix.9 The
possible clinical impact of this finding justified in vivo
animal studies. According to our PCR and RT-PCR results,
no fragments of PERV sequences were detected in tissue-
engineered heart valves after 6 months of implantation.
Furthermore, we did not detect PERV RNA-DNA isolated
from lymphocytes and plasma of sheep that underwent heart
valve replacement with tissue-engineered heart valves based
on acellularized porcine tissue. These results provide evi-
dence that acellularized porcine heart valve scaffolds used
for heart valve tissue engineering do not transmit PERV to
sheep.
Limitation of the Study
Cross-species transmission of PERV has not been demon-
strated in vivo. Although PCR and RT-PCR are sensitive
tools for detecting PERV sequences, it could be argued that
the failure to detect cross-species transmission of PERV in
this study is a methodological problem. However, the im-
plantation time of 6 months should be sufficient to detect
any PERV infection with the methods used in this study.
Other methods like electron microscopy, giving the capa-
bility to proof PERV transmission by direct proof of PERV
virus, would have added further information.
In conclusion, we did not detect PERV transmission or
infection in sheep after implantation of tissue-engineered
heart valves based on acellularized porcine matrix scaffolds.
The preliminary data from this study indicate that the chem-
ical acellularization process with trypsin/EDTA is sufficient
enough to prevent cross-species transmission of PERV in a
sheep model. However, further studies are mandatory to
draw the definite conclusion that the porcine matrix can be
used as a scaffold for heart valve tissue engineering with no
increased risk of cross-species transmission of PERV.
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